Evidence map›Paper›PMID 39036987›Full record

Trial reportThe Journal of infectious diseases2024

SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.

Nathaniel Bloom, Sydney I Ramirez, Hallie Cohn, Urvi M Parikh, Amy Heaps, Scott F Sieg, Alex Greninger, Justin Ritz, Carlee Moser, Joseph J Eron and 12 more

Abstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
In one paragraph

Trial report in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Nathaniel BloomCenter for Vaccine Innovation, La Jolla Institute for Immunology.
Sydney I RamirezCenter for Vaccine Innovation, La Jolla Institute for Immunology.
Hallie CohnDepartment of Microbiology.
Urvi M ParikhDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania.
Amy HeapsDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania.
Scott F SiegDivision of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio.
Alex GreningerDepartment of Medicine, University of Washington, Seattle.ORCID 0000-0002-7443-0527
Justin RitzCenter for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Carlee MoserCenter for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0001-5601-9112
Joseph J EronDepartment of Medicine, University of North Carolina at Chapel Hill School of Medicine.
Goran BajicDepartment of Microbiology.
Judith S CurrierDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.
Paul KlekotkaEli Lilly and Company, San Diego.
David A WohlDepartment of Medicine, University of North Carolina at Chapel Hill School of Medicine.
Eric S DaarLundquist Institute at Harbor, University of California, Los Angeles Medical Center, Torrance.
Jonathan LiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Michael D HughesCenter for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Kara W ChewDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.
Davey M SmithDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla.
Shane CrottyCenter for Vaccine Innovation, La Jolla Institute for Immunology.
Camila H CoelhoDepartment of Microbiology.ORCID 0000-0002-7885-9996
Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team

Funding

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
T follicular helper (Tfh) CD4+ T cell, germinal center, and antibody response dysfunction in human recurrent tonsillitisU19AI142742 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Shane P Crotty · 2019 to 2026
$32.8M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Seattle Vaccine Trials UnitUM1AI069481 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Rachel Ann Bender Ignacio, Margaret Juliana McElrath · 2012 to 2026
$24.4M
Units for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2M
NIH FIRST Cohort Cluster Hiring Initiative at Icahn School of Medicine at Mount SinaiU54CA267776 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENJAMIN K CHEN · 2021 to 2026
$17.4M
UCLA AIDS Prevention and Treatment Clinical Trials UnitU01AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 2007 to 2011
$13.9M
A. P. Giannini FoundationCollaborative Center for Human Immunology AI142742La Jolla Institute for Immunology institutional fundsNational Institute of Allergy and Infectious DiseasesNCI NIH HHS U54 CA267776NIAID NIH HHS 75N93019C00065NIAID NIH HHS R25 AI147376NIAID NIH HHS T32 AI007036NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069424NIAID NIH HHS U01 AI069463NIAID NIH HHS U19 AI142742NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069481NIH Faculty Institutional Recruitment for Sustainable Transformation U54CA267776NIH HHSNIH HHS 75N93019C00065
6 · The paper itself

Abstract

Therapeutic monoclonal antibodies (mAbs) have been studied in humans, but the impact on immune memory of mAb treatment during an ongoing infection remains unclear. We evaluated the effect of infusion of the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) mAb bamlanivimab on memory B cells (MBCs) in SARS-CoV-2-infected individuals. Bamlanivimab treatment skewed the repertoire of MBCs targeting spike toward non-RBD epitopes. Furthermore, the relative affinity of RBD MBCs was weaker in mAb-treated individuals compared to placebo-treated individuals over time. Subsequently, after mRNA coronavirus disease 2019 vaccination, MBC differences persisted and mapped to a specific reduction in recognition of the class II RBD site, the same RBD epitope recognized by bamlanivimab. These findings indicate a substantial role of antibody feedback in regulating MBC responses to infection, and single mAb administration can continue to impact MBC responses to additional antigen exposures months later.

Indexed as

Antibodies, MonoclonalCOVID-19Epitopes, B-LymphocyteFeedback, PhysiologicalMemory B CellsSARS-CoV-2VaccinationAdultAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralbamlanivimabCOVID-19 VaccinesEpitopes, B-LymphocyteSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2bamlanivimabCOVID-19mAb therapymemory B cellsSARS-CoV-2

Identifiers

PMID39036987
PMCPMC11566236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.